These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31901056)

  • 1. Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases.
    Edo-Solsona MD; Vitoria-Miñana I; Poveda-Andrés JL
    Farm Hosp; 2020 Jan; 44(1):10-15. PubMed ID: 31901056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating lysosomal storage disorders: What have we learnt?
    Lachmann RH
    J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [How does the landscape change in lysosomal storage disease].
    Parini R
    Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatable lysosomal storage diseases in the advent of disease-specific therapy.
    Peters H; Ellaway C; Nicholls K; Reardon K; Szer J
    Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for LSDs: no longer just enzyme replacement therapy for Gaucher disease. Foreword.
    Cohen IJ; Baris H; Mistry PK
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():58. PubMed ID: 24380122
    [No Abstract]   [Full Text] [Related]  

  • 7. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enzyme replacement therapy of lysosomal storage diseases].
    Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of the treatment of lysosomal deposit diseases: Analysis of 22 patients.
    Canales-Siguero D; García-Muñoz C; Quijada Fraile P; Morales Conejo M; Ferrari-Piquero JM; Martín-Hernández E
    Med Clin (Barc); 2022 Oct; 159(8):380-384. PubMed ID: 35688745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world patient data on immunity and COVID-19 status of patients with MPS, Gaucher, and Pompe diseases from Turkey.
    Kilavuz S; Kor D; Bulut FD; Serbes M; Karagoz D; Altıntas DU; Bisgin A; Seydaoğlu G; Mungan HNO
    Arch Pediatr; 2022 Aug; 29(6):415-423. PubMed ID: 35705384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders.
    Henley WE; Anderson LJ; Wyatt KM; Nikolaou V; Anderson R; Logan S
    J Inherit Metab Dis; 2014 Nov; 37(6):939-44. PubMed ID: 24519353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for lysosomal storage diseases.
    Beck M
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):495-507. PubMed ID: 20557271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory watch: enhanced chance of success for protein replacement therapies.
    Crunkhorn S
    Nat Rev Drug Discov; 2013 Jun; 12(6):414. PubMed ID: 23722335
    [No Abstract]   [Full Text] [Related]  

  • 17. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review.
    Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A
    Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.
    Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J
    Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drug development.
    Pastores GM; Gupta P
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():64-7. PubMed ID: 24380124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.